tiprankstipranks
CARsgen Therapeutics Holdings Ltd. (HK:2171)
:2171
Hong Kong Market

CARsgen Therapeutics Holdings Ltd. (2171) Price & Analysis

Compare
1 Followers

2171 Stock Chart & Stats


---

Financials

Quarterly

Options Prices

Currently, No data available
---

Ownership Overview

1.79%97.16%
Insiders
― Other Institutional Investors
97.16% Public Companies and
Individual Investors

2171 FAQ

What was CARsgen Therapeutics Holdings Ltd.’s price range in the past 12 months?
CARsgen Therapeutics Holdings Ltd. lowest stock price was HK$2.48 and its highest was HK$13.40 in the past 12 months.
    What is CARsgen Therapeutics Holdings Ltd.’s market cap?
    CARsgen Therapeutics Holdings Ltd.’s market cap is HK$7.28B.
      When is CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date?
      CARsgen Therapeutics Holdings Ltd.’s upcoming earnings report date is Mar 18, 2025 which is in 24 days.
        How were CARsgen Therapeutics Holdings Ltd.’s earnings last quarter?
        CARsgen Therapeutics Holdings Ltd. released its earnings results on Aug 28, 2024. The company reported -HK$0.676 earnings per share for the quarter, missing the consensus estimate of -HK$0.279 by -HK$0.397.
          Is CARsgen Therapeutics Holdings Ltd. overvalued?
          According to Wall Street analysts CARsgen Therapeutics Holdings Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does CARsgen Therapeutics Holdings Ltd. pay dividends?
            CARsgen Therapeutics Holdings Ltd. does not currently pay dividends.
            What is CARsgen Therapeutics Holdings Ltd.’s EPS estimate?
            CARsgen Therapeutics Holdings Ltd.’s EPS estimate is -0.43.
              How many shares outstanding does CARsgen Therapeutics Holdings Ltd. have?
              CARsgen Therapeutics Holdings Ltd. has 571,978,000 shares outstanding.
                What happened to CARsgen Therapeutics Holdings Ltd.’s price movement after its last earnings report?
                CARsgen Therapeutics Holdings Ltd. reported an EPS of -HK$0.676 in its last earnings report, missing expectations of -HK$0.279. Following the earnings report the stock price went down -0.824%.
                  Which hedge fund is a major shareholder of CARsgen Therapeutics Holdings Ltd.?
                  Currently, no hedge funds are holding shares in HK:2171
                  ---

                  CARsgen Therapeutics Holdings Ltd. Stock Smart Score

                  7
                  Neutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Company Description

                  CARsgen Therapeutics Holdings Ltd.

                  CARsgen Therapeutics Holdings Ltd is primarily engaged in discovering, developing, and commercializing innovative cell therapies in China and the...
                  ---

                  2171 Stock 12 Month Forecast

                  Average Price Target

                  HK$8.96
                  ▼(-29.56% Downside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"HK$7","20":"HK$20","10.25":"HK$10.25","13.5":"HK$13.5","16.75":"HK$16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$8.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$8.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$8.96</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,10.25,13.5,16.75,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2023","6":"Apr<br/>2023","9":"Jul<br/>2023","12":"Feb<br/>2025","25":"Feb<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.2,10.104615384615384,10.009230769230768,9.913846153846153,9.818461538461538,9.723076923076922,9.627692307692307,9.532307692307693,9.436923076923078,9.341538461538462,9.246153846153847,9.150769230769232,9.055384615384616,{"y":8.96,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.2,10.104615384615384,10.009230769230768,9.913846153846153,9.818461538461538,9.723076923076922,9.627692307692307,9.532307692307693,9.436923076923078,9.341538461538462,9.246153846153847,9.150769230769232,9.055384615384616,{"y":8.96,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.2,10.104615384615384,10.009230769230768,9.913846153846153,9.818461538461538,9.723076923076922,9.627692307692307,9.532307692307693,9.436923076923078,9.341538461538462,9.246153846153847,9.150769230769232,9.055384615384616,{"y":8.96,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.12,"date":1664582400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.76,"date":1667260800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.66,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.98,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.78,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.06,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.7,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.94,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.64,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.69,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.14,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.14,"date":1690848000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.2,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Sino Biopharmaceutical
                  Innovent Biologics
                  Wuxi Biologics (Cayman)
                  Peijia Medical Ltd.
                  CanSino Biologics, Inc. Class H

                  Best Analysts Covering 2171

                  1 Year
                  Ziyi ChenGoldman Sachs
                  1 Year Success Rate
                  1/1 ratings generated profit
                  100%
                  1 Year Average Return
                  +2.50%
                  downgraded a sell rating 17 days ago
                  Copying Ziyi Chen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +2.50% per trade.
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis